Brind.

The FDA approved the SAPIEN 3 TAVR therapy, while the company simultaneously faced removal from Russell indices.

1 report, 0 independent Updated Jul 1

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

FDA Edwards Lifesciences RUSSELL

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Edwards Lifesciences
American medical technology company
- Edwards Lifesciences and InspireMD were compared in a market analysis.Sat 11:51
RUSSELL
rapper
- Lee's Summit is in Jackson County, and local figures like RUSSELL and Baird are involved in community activities and commerce.Sat 06:59
- Third Avenue Small-Cap Value Fund outperformed the MSCI index in Q2 2026 and added CRA International as a new holding.Tue 17:24

Related events

FDA approved expanded use of Sapien 3 valves, while Edwards conducts Progress trials and seeks expanded Medicare coverage for TAVR.Sep 21

Coverage

Newest first; wire copies grouped

Jul 1Unknown outlet